GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

President Donald Trump bragged about having a "good memory" this evening, as reporters questioned how he prepared to host the ...

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Administering an amino acid used to treat high blood pressure also appears to reverse signs of dementia in mice.

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...

The researchers assessed the association between Alzheimer’s biomarkers and body mass index (BMI), according to a press ...